KLOW
Research Use Only | Not for Human Consumption
A four-peptide research blend of GHK-Cu, BPC-157, TB-500, and KPV supplied in lyophilized form.
Blend Components
| Component | CAS# | Formula | Molar Mass |
|---|---|---|---|
| CAS Number: GHK-Cu | Molecular Formula: 49557-75-7 | Molar Mass: C14H22CuN6O4 | 401.91 g/mol |
| BPC-157 | 137525-51-0 | C62H98N16O22 | 1419.55 g/mol |
| TB-500 | 77591-33-4 | C212H350N56O78S | 4963.44 g/mol |
| KPV | 67727-97-3 | C16H30N4O4 | 342.43 g/mol |
· Free 2-day shipping
Four-peptide research blend for tissue and cellular research applications
KLOW is a multi-peptide research blend for studying tissue remodeling, cellular migration, collagen synthesis, and anti-inflammatory signaling pathways in vitro. It builds on the GLOW three-peptide combination—GHK-Cu, BPC-157, and TB-500—by adding KPV, the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH, to enable parallel investigation of extracellular matrix mechanisms and melanocortin-related signaling.
What is KLOW?
KLOW assembles four peptides that each entered the research literature along separate paths. GHK-Cu, a copper-binding tripeptide, was first described by Loren Pickart in the 1970s and has since been examined in vitro for associations with gene-expression and matrix-remodeling pathways. BPC-157 emerged in the early 1990s from Croatian researchers studying gastric protective fractions, while TB-500 (Thymosin Beta-4) traces to Allan Goldstein's thymosin work at the National Institutes of Health in the 1960s.
The fourth component, KPV, is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been investigated in preclinical research for anti-inflammatory and melanocortin-related signaling pathways, including studies of intestinal epithelial cell models. KPV is what distinguishes KLOW from the three-peptide GLOW blend: KLOW pairs GLOW's extracellular-matrix-focused peptides with an additional tripeptide studied for distinct inflammatory-signaling mechanisms.
Combining the four peptides lets researchers examine complementary in-vitro mechanisms—matrix and collagen signaling, angiogenesis, cellular migration, and melanocortin-related inflammatory pathways—within a single lyophilized preparation. This product is intended for research use only.
How should KLOW be stored?
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Prepared samples must be stored in the fridge to maintain stability, and remain stable for up to 30 days when properly refrigerated.
Certificate of Analysis
Every batch of KLOW is tested by ILS Laboratories, an ISO/IEC 17025–accredited lab, for purity, identity, heavy metals, sterility, endotoxin, and a fentanyl screen. The full certificate is below.
GHK-Cu / TB-500 / BPC-157 / KPV · 50mg/10mg/10mg/10mg
Peptide Purity · HPLC @ 214 nm
99.61% — exceptional research-grade purity
Area-normalized against all peptide-related peaks. Identity confirmed by chromatographic retention-time match to a reference standard.
Every test on this certificate
COA documents are updated with each new batch. Contact support for batch-specific documentation.
References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108.
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
